Cargando…

Ways to Eliminate Viral Hepatitis as a Global Health Threat

Detalles Bibliográficos
Autores principales:	Flisiak, Robert, Zarębska-Michaluk, Dorota, Flisiak-Jackiewicz, Marta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317760/ https://www.ncbi.nlm.nih.gov/pubmed/35891534 http://dx.doi.org/10.3390/v14071554

Ejemplares similares

Updates in Management of SARS-CoV-2 Infection
por: Flisiak, Robert, et al.
Publicado: (2022)

Perspectives of hepatitis C virus (HCV) elimination in Poland
por: Flisiak, Robert, et al.
Publicado: (2019)

Early oral antiviral use in patients hospitalised with COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C
por: Brzdęk, Michał, et al.
Publicado: (2023)

How close are we to hepatitis C virus elimination in Central Europe?
por: Flisiak, Robert, et al.
Publicado: (2020)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Changing Epidemiological Patterns of Infection and Mortality Due to Hepatitis C Virus in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Viral hepatitis C treatment shortening – what is the limit?
por: Zarębska-Michaluk, Dorota
Publicado: (2019)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

Trends of infections and mortality due to hepatitis B virus (2005-2022) and the potential impact of the COVID-19 pandemic: a population-based study in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Chronic Viral Hepatitis and Metabolic Syndrome/Cardiovascular Risk
por: Jarcuska, Peter, et al.
Publicado: (2018)

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study
por: Pawlowska, Malgorzata, et al.
Publicado: (2023)

Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children
por: Flisiak-Jackiewicz, Marta, et al.
Publicado: (2019)

Searching for the optimal population for hepatitis C virus screening in Poland
por: Piekarska, Anna, et al.
Publicado: (2020)

Global Elimination of HCV—Why Is Poland Still So Far from the Goal?
por: Tronina, Olga, et al.
Publicado: (2023)

HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons
por: Flisiak, Robert, et al.
Publicado: (2022)

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
por: Flisiak, Robert, et al.
Publicado: (2021)

The challenges of viral hepatitis elimination: a global response to a global problem
por: Black, Antony P., et al.
Publicado: (2023)

Genotype 3-hepatitis C virus’ last line of defense
por: Zarębska-Michaluk, Dorota
Publicado: (2021)

From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
por: Flisiak-Jackiewicz, Marta, et al.
Publicado: (2021)

Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
por: Rzymski, Piotr, et al.
Publicado: (2021)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings
por: Dobrowolska, Krystyna, et al.
Publicado: (2023)

Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection
por: Parfieniuk-Kowerda, Anna, et al.
Publicado: (2015)

Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017
por: Smith, Shanley, et al.
Publicado: (2019)

Shear-wave elastography for evaluation of hepatic stiffness in chronic viral hepatitis B and C
por: Martonik, Diana, et al.
Publicado: (2023)

Variability in the Clinical Course of COVID-19 in a Retrospective Analysis of a Large Real-World Database
por: Flisiak, Robert, et al.
Publicado: (2023)

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Celiac Disease in Conjunction with Hereditary Fructose Intolerance as a Rare Cause of Liver Steatosis with Mild Hypertransaminasemia—A Case Report
por: Bobrus-Chociej, Anna, et al.
Publicado: (2021)

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era
por: Brzdęk, Michał, et al.
Publicado: (2023)

Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant
por: Flisiak, Robert, et al.
Publicado: (2023)

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Predictive Role of Interleukin-18 in Liver Steatosis in Obese Children
por: Flisiak-Jackiewicz, Marta, et al.
Publicado: (2018)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Wildlife Trade: Threat to Global Health
por: Pearl, Mary C.
Publicado: (2004)

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study
por: Janczewska, Ewa, et al.
Publicado: (2015)

MERS—the latest threat to global health security
por: The Lancet
Publicado: (2015)

Retreatment of symptomatic hepatitis C virus genotype 3 associated mixed cryoglobulinemia with sofosbuvir and ribavirin: a case report
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_50j395uaehn8kpqql02ctvm2gn